Search Results 1061-1070 of 15395 for alt

1. A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency - Mayo Clinic

   Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 × ULN;; Bilirubin ≤ 1.5 × ULN (< 2 x ULN if hyperbilirubinemia is due to Gilbert's ...

2. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer - Mayo Clinic

   Hepatic: Aspartate transaminase (AST) / Alanine transaminase (ALT) ≤ 2.5 x upper limit of normal (ULN) (if liver metastases are present, ≤ 5 x ULN); Total or ...

3. Adipose-Derived Mesenchymal Stem Cells (AMSCs) For Recurrent Glioblastoma - Mayo Clinic

   ALT, AST and alkaline phosphatase ≤ 3 times the upper limit of normal, and bilirubin ≤ 2.5 mg/dL;; Prothrombin time ≤1.5 times upper limit of normal;; INR ...

4. Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients

   Aspartate transaminase (AST) or alanine transaminase (ALT) ≤3 x ULN, unless considered due to organ leukemic involvement. Women of child-bearing potential ...

5. Study to Evaluate the Safety and Effectiveness of BMS-986036 in Adults with Nonalcoholic Steatophepatitis (NASH) and Stage 3 Liver Fibrosis - Mayo Clinic

   ALT value > 5× the upper limit of normal (ULN) as defined by the central ... Evidence of significant worsening of ALT, AST or bilirubin during the ...

6. Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer - Mayo Clinic

   AST (SGOT)/ALT (SGPT) ≤ 2.5 X institutional upper limit of normal;; Albumin ≥ 3.0 g/dL. Patients known to be Human immunodeficiency virus (HIV)+ are ...

7. A Study to Evaluate Adjuvant Ado-Trastuzumab Emtansine (T-DM1) in HER2 Positive Breast Cancer - Mayo Clinic

   NOTE: Patients with positive Hepatitis B or C serologies indicating active infection without known active disease must meet the eligibility requirements for ALT ...

8. A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease - Mayo Clinic

   -Impaired liver function, defined as total bilirubin > 1.5 × ULN and/or ALT and AST > 3 × ULN in participants with no evidence of liver cGVHD. -Currently ...

9. Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade Glioma - Mayo Clinic

   Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN (obtained ≤ 14 days prior to registration); Total serum bilirubin ≤ 1.5 x ...

10. A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Fruquintinib in Patients with Solid Tumors - Mayo Clinic

    Alanine aminotransferase (ALT) aspartate aminotransferase (AST) > 1.5 ULN in patients without hepatic metastases or ALT, AST > 3 ULN in patients with hepatic ...